Novo And Lilly Head For Diabetes Pricing Battle - Seeking Alpha


Xconomy

Novo And Lilly Head For Diabetes Pricing Battle
Seeking Alpha
Novo Nordisk (NYSE:NVO) needs its once-weekly GLP1 agonist semaglutide to be a smash hit, and a head-to-head win against Lilly's (NYSE:LLY) rival product Trulicity suggests that it could be. FDA approval of semaglutide - which has a PDUFA date of ...
Novo Nordisk's new semaglutide trounces Lilly's scrappy Trulicity in diabetes trialFiercePharma
Novo Nordisk Diabetes Drug Beats Lilly's Trulicity in Head-to-Head TestXconomy
Novo Nordisk's New Type 2 Diabetes Drug Outperforms Eli Lilly'sLabiotech.eu (blog)
Business Insider -Investor's Business Daily -STAT
all 106 news articles »


from diabetes - Google News